Progression-Free Survival in MM

Progression-Free Survival in MM

obr

6 months
25 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers explains the significance of the prolonged progression-free survival in patients with relapsed/refractory multiple myeloma (MM) if treating with isatuximab.
Up Next Autoplay
Multiple Myeloma Disparities #ASH19 @WinshipAtEmory
Multiple Myeloma Disparities #ASH19 @WinshipAtEmory
Category: Multiple Myeloma
23 Views
ash 4 weeks
GRIFFIN Study Update #ASH19 @LevineCancer
GRIFFIN Study Update #ASH19 @LevineCancer
Category: Multiple Myeloma
3 Views
ash 1 month
Phase 1 Clinical Study (CRB-402) of bb21217 #ASH19 @BerdejaJesus
Phase 1 Clinical Study (CRB-402) of bb21217 #ASH19 @BerdejaJesus
Category: Multiple Myeloma
11 Views
ash 1 month
ICARIA-MM: What's Next? #ASH19
ICARIA-MM: What's Next? #ASH19
Category: Multiple Myeloma
6 Views
ash 1 month
ICARIA-MM #ASH19
ICARIA-MM #ASH19
Category: Multiple Myeloma
24 Views
ash 1 month
RRMM Patients Treated with IRd: How This Affects Clinicians #ASH19 @TakedaOncology
RRMM Patients Treated with IRd: How This Affects Clinicians #ASH19 @TakedaOncology
Category: Multiple Myeloma
6 Views
ash 1 month
Outcomes in RRMM Patients Treated with IRd #ASH19 @TakedaOncology
Outcomes in RRMM Patients Treated with IRd #ASH19 @TakedaOncology
Category: Multiple Myeloma
5 Views
ash 1 month
MAIA Study Update #ASH19
MAIA Study Update #ASH19
Category: Multiple Myeloma
40 Views
ash 1 month
HORIZON Study #ASH19 @RushMedical
HORIZON Study #ASH19 @RushMedical
Category: Multiple Myeloma
19 Views
ash 1 month
Phase I Study Evaluating NKTR-255 in MM and NHL #ASH #ASH19 @DanaFarber
Phase I Study Evaluating NKTR-255 in MM and NHL #ASH #ASH19 @DanaFarber
Category: Multiple Myeloma
11 Views
ash 1 month